Verastem. has filed a patent for a method involving administering a FAK inhibitor and an immunotherapeutic agent like anti-PD-1 or anti-PD-L1 for treating abnormal cell growth, particularly cancer, in mammals, including humans. The combination aims to enhance treatment efficacy by targeting the immune checkpoint blockade pathway. GlobalData’s report on Verastem gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Verastem, Cancer treatment biomarkers was a key innovation area identified from patents. Verastem's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Combination treatment of fak inhibitor and immunotherapy for cancer
See Also:
A patent application (Publication Number: US20240000790A1) discloses a method for treating human subjects with diseases like cancer by administering a FAK inhibitor in combination with an immunotherapeutic agent. The immunotherapeutic agent can be a compound that inhibits the immune checkpoint blockade pathway. The method specifies various types of cancers that can be treated using this approach, including mesothelioma, breast cancer, ovarian cancer, lung cancer, melanoma, colorectal cancer, leukemia, adenocarcinoma, and solid tumors. The FAK inhibitor can be administered orally, with specific examples like VS-4718, VS-6063, and others mentioned in the claims.
Furthermore, the method involves the use of different immunotherapeutic agents such as anti-CTLA-4 antibodies, anti-PD-1 ligands, anti-PD-1 antibodies, anti-PD-L1 antibodies, checkpoint blocking antibodies, cell-based therapies like CAR-T therapy, and co-stimulatory antibodies. The treatment approach may also include additional chemotherapeutic agents, radiation therapy, and cytotoxic agents like gemcitabine or paclitaxel. The claims provide a detailed framework for combining FAK inhibitors with various immunotherapeutic strategies to target different types of cancers effectively, potentially offering new avenues for personalized treatment options in oncology.
To know more about GlobalData’s detailed insights on Verastem, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
